市場調查報告書

廣泛性焦慮症 (GAD) - 市場考察,流行病學,市場預測:2028年

General Anxiety Disorder (GAD) - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 923101
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
廣泛性焦慮症 (GAD) - 市場考察,流行病學,市場預測:2028年 General Anxiety Disorder (GAD) - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家的廣泛性焦慮症 (GAD) 市場在2017年估算達到約19億1698萬美元。

本報告提供全球廣泛性焦慮症 (GAD) 市場相關調查分析,提供疾病的背景,流行病學,主要7個國家(美國,德國,西班牙,義大利,法國,英國,日本)的市場趨勢相關的系統性資訊。

目錄

第1章 主要考察

第2章 廣泛性焦慮症 (GAD) :市場概要

  • 2017年的GAD的整體市場佔有率 (%) 分佈
  • 2028年的GAD的整體市場佔有率 (%) 分佈

第3章 主要概要

第4章 流行病學與市場的調查方法

第5章 疾病的背景和概要:廣泛性焦慮症 (GAD)

  • 簡介
  • 症狀
  • 病理生理學
  • 危險因素
  • 診斷

第6章 流行病學和患者族群:廣泛性焦慮症 (GAD)

  • 主要調查結果
  • 主要7個國家的廣泛性焦慮症 (GAD)的12個月整體患者數
  • 美國
  • EU5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 目前治療

  • 特別的族群的治療
  • 治療指南

第8章 未滿足需求

第9章 病例報告

第10章 上市藥

  • 主要的交叉競爭 - 主要治療方法

第11章 新興藥

  • 主要的交叉競爭
  • 主要的交叉競爭 - 潛在的治療方法
  • Troriluzole:BioHaven Pharmaceuticals
  • Escitalopram:Allergan

第12章 市場規模:廣泛性焦慮症 (GAD)

  • 主要調查結果
  • 主要7個國家的廣泛性焦慮症 (GAD)的整體市場規模
  • 主要7個國家的廣泛性焦慮症 (GAD)的整體市場規模:各治療法

第13章 市場預測:主要7個國家

  • 美國
  • EU5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第14章 推動市場要素

第15章 市場障礙

第16章 參考文獻

第17章 附錄

第18章 DelveInsight的功能

第19章 免責事項

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0824

DelveInsight's "General Anxiety Disorder (GAD) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the General Anxiety Disorder (GAD), historical and forecasted epidemiology as well as the General Anxiety Disorder (GAD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The General Anxiety Disorder (GAD) market report provides current treatment practices, emerging drugs, General Anxiety Disorder (GAD) market share of the individual therapies, current and forecasted General Anxiety Disorder (GAD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current General Anxiety Disorder (GAD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

General Anxiety Disorder (GAD) Disease Understanding and Treatment Algorithm

The DelveInsight General Anxiety Disorder (GAD) market report gives a thorough understanding of the General Anxiety Disorder (GAD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for General Anxiety Disorder (GAD).

Treatment

It covers the details of conventional and current medical therapies available in the General Anxiety Disorder (GAD) market for the treatment of the condition. It also provides General Anxiety Disorder (GAD) treatment algorithms and guidelines in the United States, Europe, and Japan.

General Anxiety Disorder (GAD) Epidemiology

The General Anxiety Disorder (GAD) epidemiology division provide insights about historical and current General Anxiety Disorder (GAD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted General Anxiety Disorder (GAD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- General Anxiety Disorder (GAD) Epidemiology

The epidemiology segment also provides the General Anxiety Disorder (GAD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

General Anxiety Disorder (GAD) Drug Chapters

Drug chapter segment of the General Anxiety Disorder (GAD) report encloses the detailed analysis of General Anxiety Disorder (GAD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the General Anxiety Disorder (GAD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for General Anxiety Disorder (GAD) treatment.

General Anxiety Disorder (GAD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for General Anxiety Disorder (GAD) treatment.

General Anxiety Disorder (GAD) Market Outlook

The General Anxiety Disorder (GAD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted General Anxiety Disorder (GAD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of General Anxiety Disorder (GAD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, General Anxiety Disorder (GAD) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the General Anxiety Disorder (GAD) market in 7MM.

The United States Market Outlook

This section provides the total General Anxiety Disorder (GAD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total General Anxiety Disorder (GAD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total General Anxiety Disorder (GAD) market size and market size by therapies in Japan is also mentioned.

General Anxiety Disorder (GAD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the General Anxiety Disorder (GAD) market or expected to get launched in the market during the study period 2017-2030. The analysis covers General Anxiety Disorder (GAD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

General Anxiety Disorder (GAD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses General Anxiety Disorder (GAD) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for General Anxiety Disorder (GAD) emerging therapies.

Reimbursement Scenario in General Anxiety Disorder (GAD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in General Anxiety Disorder (GAD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or General Anxiety Disorder (GAD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the General Anxiety Disorder (GAD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of General Anxiety Disorder (GAD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the General Anxiety Disorder (GAD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for General Anxiety Disorder (GAD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of General Anxiety Disorder (GAD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global General Anxiety Disorder (GAD) market

Report Highlights

  • In the coming years, General Anxiety Disorder (GAD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence General Anxiety Disorder (GAD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for General Anxiety Disorder (GAD). Launch of emerging therapies will significantly impact the General Anxiety Disorder (GAD) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for General Anxiety Disorder (GAD)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

General Anxiety Disorder (GAD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • General Anxiety Disorder (GAD) Pipeline Analysis
  • General Anxiety Disorder (GAD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

General Anxiety Disorder (GAD) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

General Anxiety Disorder (GAD) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

General Anxiety Disorder (GAD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the General Anxiety Disorder (GAD) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the General Anxiety Disorder (GAD) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest General Anxiety Disorder (GAD) market size during the forecast period (2017-2030)?
  • At what CAGR, the General Anxiety Disorder (GAD) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the General Anxiety Disorder (GAD) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the General Anxiety Disorder (GAD) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the General Anxiety Disorder (GAD)?
  • What is the historical General Anxiety Disorder (GAD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of General Anxiety Disorder (GAD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to General Anxiety Disorder (GAD)?
  • Out of all 7MM countries, which country would have the highest prevalent population of General Anxiety Disorder (GAD) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the General Anxiety Disorder (GAD) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of General Anxiety Disorder (GAD) in the USA, Europe, and Japan?
  • What are the General Anxiety Disorder (GAD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of General Anxiety Disorder (GAD)?
  • How many therapies are developed by each company for General Anxiety Disorder (GAD) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for General Anxiety Disorder (GAD) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the General Anxiety Disorder (GAD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for General Anxiety Disorder (GAD) and their status?
  • What are the key designations that have been granted for the emerging therapies for General Anxiety Disorder (GAD)?
  • What are the global historical and forecasted market of General Anxiety Disorder (GAD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the General Anxiety Disorder (GAD) market
  • To understand the future market competition in the General Anxiety Disorder (GAD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for General Anxiety Disorder (GAD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for General Anxiety Disorder (GAD) market
  • To understand the future market competition in the General Anxiety Disorder (GAD) market

Table of Contents

1. Key Insights

2. Executive Summary of General Anxiety Disorder (GAD)

3. Competitive Intelligence Analysis for General Anxiety Disorder (GAD)

4. General Anxiety Disorder (GAD): Market Overview at a Glance

  • 4.1. General Anxiety Disorder (GAD) Total Market Share (%) Distribution in 2017
  • 4.2. General Anxiety Disorder (GAD) Total Market Share (%) Distribution in 2030

5. General Anxiety Disorder (GAD): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. General Anxiety Disorder (GAD) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. General Anxiety Disorder (GAD) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. General Anxiety Disorder (GAD) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. General Anxiety Disorder (GAD) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. General Anxiety Disorder (GAD) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. General Anxiety Disorder (GAD) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. General Anxiety Disorder (GAD) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. General Anxiety Disorder (GAD) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. General Anxiety Disorder (GAD) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. General Anxiety Disorder (GAD) Treatment and Management
  • 8.2. General Anxiety Disorder (GAD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of General Anxiety Disorder (GAD) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. General Anxiety Disorder (GAD): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. General Anxiety Disorder (GAD) Market Size in 7MM
  • 13.3. General Anxiety Disorder (GAD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. General Anxiety Disorder (GAD) Total Market Size in the United States
    • 15.1.2. General Anxiety Disorder (GAD) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. General Anxiety Disorder (GAD) Total Market Size in Germany
    • 15.3.2. General Anxiety Disorder (GAD) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. General Anxiety Disorder (GAD) Total Market Size in France
    • 15.4.2. General Anxiety Disorder (GAD) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. General Anxiety Disorder (GAD) Total Market Size in Italy
    • 15.5.2. General Anxiety Disorder (GAD) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. General Anxiety Disorder (GAD) Total Market Size in Spain
    • 15.6.2. General Anxiety Disorder (GAD) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. General Anxiety Disorder (GAD) Total Market Size in the United Kingdom
    • 15.7.2. General Anxiety Disorder (GAD) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. General Anxiety Disorder (GAD) Total Market Size in Japan
    • 15.8.3. General Anxiety Disorder (GAD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of General Anxiety Disorder (GAD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM General Anxiety Disorder (GAD) Epidemiology (2017-2030)
  • Table 2 : 7MM General Anxiety Disorder (GAD) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : General Anxiety Disorder (GAD) Epidemiology in Germany (2017-2030)
  • Table 6 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : General Anxiety Disorder (GAD) Epidemiology in France (2017-2030)
  • Table 8 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : General Anxiety Disorder (GAD) Epidemiology in Italy (2017-2030)
  • Table 10 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : General Anxiety Disorder (GAD) Epidemiology in Spain (2017-2030)
  • Table 12 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : General Anxiety Disorder (GAD) Epidemiology in the UK (2017-2030)
  • Table 14 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : General Anxiety Disorder (GAD) Epidemiology in Japan (2017-2030)
  • Table 16 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM General Anxiety Disorder (GAD) Epidemiology (2017-2030)
  • Figure 2 : 7MM General Anxiety Disorder (GAD) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : General Anxiety Disorder (GAD) Epidemiology in the United States (2017-2030)
  • Figure 4 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : General Anxiety Disorder (GAD) Epidemiology in Germany (2017-2030)
  • Figure 6 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : General Anxiety Disorder (GAD) Epidemiology in France (2017-2030)
  • Figure 8 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : General Anxiety Disorder (GAD) Epidemiology in Italy (2017-2030)
  • Figure 10 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : General Anxiety Disorder (GAD) Epidemiology in Spain (2017-2030)
  • Figure 12 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : General Anxiety Disorder (GAD) Epidemiology in the UK (2017-2030)
  • Figure 14 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : General Anxiety Disorder (GAD) Epidemiology in Japan (2017-2030)
  • Figure 16 : General Anxiety Disorder (GAD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)